Vanda Pharmaceuticals | VNDA - Passivo Circulante





Passivo Circulante Alterar Data
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
Akebia Therapeutics USD 162.94M 29.56M 2025-12
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Anika Therapeutics USD 20.97M 942K 2026-03
Arrowhead Research USD 347.42M 151.94M 2025-12
AstraZeneca USD 32.57B 1.95B 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Eli Lilly USD 36.63B 1.41B 2026-03
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Esperion Therapeutics USD 300.81M 58.22M 2025-12
Halozyme Therapeutics USD 177.09M 660.14M 2025-12
Heron Therapeutics USD 96.1M 6.39M 2025-12
Insmed USD 468.87M 51.66M 2025-12
J&J USD 57.72B 3.59B 2026-03
Lexicon Pharmaceuticals USD 20.87M 853K 2025-12
Ligand Pharmaceuticals USD 37.45M 6.91M 2025-12
Merck USD 26.94B 1.38B 2026-03
Minerva Neurosciences USD 2.29M 381K 2025-12
Moderna USD 2.4B 408M 2026-03
Novartis USD 27.28B 4.72B 2025-12
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 968.43M 102.18M 2025-12
Puma Biotechnology USD 82.73M 3.63M 2025-09
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sanofi EUR 30.01B 1.66B 2026-03
Takeda JPY 2.61T 470.53B 2025-12
Teva Pharmaceutical Industries USD 13.53B 76M 2026-03
Ultragenyx Pharmaceutical USD 384M 43.98M 2025-12
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12
Veracyte USD 59.94M 12.22M 2025-12